Cytokinetics (CYTK) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $62.99 -0.51%
Revenue Growth %: +2,004.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +2,004.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.50), $0.13 better than the analyst estimate of ($1.63). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $17.09 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Updates US Conviction List Directors' Cut
- These 3 EU chip stocks screen as most de-risked sector bets: UBS
- Oil States International (OIS) PT Lowered to $11 at Raymond James
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
